About MTM Laboratories
MTM Laboratories is a Healthcare company based in Tucson (United States) founded in 1999 by Peter Pack, and was acquired by Roche in July 2011. In vitro diagnostics for early cervical cancer detection are manufactured. MTM Laboratories has raised $76.07 million across 8 funding rounds from investors including Roche, HBM Healthcare Investments and Wellington Partners Venture Capital. Its chief executive, as recorded, is Peter Pack. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Women's Cancer. Its competitors include Teal Health, Femasys and OncoHealth; 3 of its 3 listed competitors have raised funding.
Company details
MTM laboratories is a manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. It markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer CINtec p16 (E6H4) immunochemistry detects the over-expression of the cellular protein p16INK4a in cervical tissue and cytology specimens correlated with high-risk HPV-mediated oncogenic transformation. The company was acquired by Ventana (Roche group company) in 2011.
- Headquarters Tucson, United States
- Founders Peter Pack
- Stage Acquired
- SectorsHealthcare
- Website mtm-laboratories.com
- Acquired by Roche (Jul 2011)
Funding Insights of MTM Laboratories
MTM Laboratories has successfully raised a total of $76.07M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $9.82 million completed in November 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $76.07M
- Total Rounds 8
- Last Round Series C β $9.82M
- First Round $1.67M
(Aug 1999)
- Investors Count 9
All 8 funding rounds of MTM Laboratories with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2010 | $9.82M | Series C | β | β | |
| Oct 2009 | $10.2M | Series C | β | LBBW Venture Capital | |
| Apr 2008 | $15.23M | Series C | β | National Technology Enterprises Company | |
| Oct 2006 | $27.71M | Series C | β | HBM Partners | |
| May 2003 | $10.54M | Series B | β | β | |
| Jun 2002 | $900,000 | Series A | β | MBG | β |
| May 2001 | $2.66M | Debt – Conventional | β | β | β |
| Aug 1999 | $1.67M | Series A | β | β |
10 investors in total: 10 institutional.
Investors in MTM Laboratories
MTM Laboratories has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, HBM Healthcare Investments and Wellington Partners Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in early-stage healthcare startups. | wellington-partners.com | Munich, Germany | ||
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
| hd-innovation.de | ||||
NTEC Kuwait is engaged in technology and knowledge transfer services. | ntec.com.kw | Kuwait City, Kuwait | ||
Early-stage VC firm investing in smart & deep-tech, fin-tech and life science & health-tech sectors | lbbwvc.de | Stuttgart, Germany | ||
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
Venture capital firm focused on small and mid-sized companies | mbg.de | Stuttgart, Germany | ||
| nexusmp.com | ||||
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for MTM Laboratories
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MTM Laboratories
1 people are tracked at MTM Laboratories (1 in leadership).
| Name | Role | Group |
|---|---|---|
Peter Pack | Founder & CEO | Leadership |
Complete people profiles for MTM Laboratories
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MTM Laboratories
4 dated milestones of MTM Laboratories across 12 years, from founding to its latest funding, stage changes and deals.
- Founded MTM Laboratories is founded.
- Funding First funding round of $1.7M.
- Funding Latest funding round, Series C, of $9.8M.
- Exit Acquired by Roche.
Competitors of MTM Laboratories
MTM Laboratories has 3 listed competitors in our database, 3 of them funded. They include Teal Health, Femasys and OncoHealth.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| getteal.com | 2020 | San Francisco, United States | $43.25M | 6 | Cervical cancer screening kits are provided by Teal Health. | |
| femasys.com | 2004 | Atlanta, United States | $69.22M | 25 | Medical devices for women's healthcare are developed and provided. | |
| oncohealth.us | 2009 | Atlanta, United States | $84.5M | OncoHealth is focused on delivering oncology-focused digital health solutions. |
Detailed competitors of MTM Laboratories
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as MTM Laboratories (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MTM Laboratories
MTM Laboratories was founded in 1999.
MTM Laboratories is headquartered in Tucson, United States. It is registered at Tucson, Arizona, United States.
Peter Pack is the CEO of MTM Laboratories, as recorded in our data. They have also founded this company.
MTM Laboratories is a funded company, having raised a total of $76.07M across 8 funding rounds to date. The company's 1st funding round was a Series A of $1.67M, raised on Aug 1999.
MTM laboratories is a manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. It markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer CINtec p16 (E6H4) immunochemistry detects the over-expression of the cellular protein p16INK4a in cervical tissue and cytology specimens correlated with high-risk HPV-mediated oncogenic transformation. The company was acquired by Ventana (Roche group company) in 2011.
MTM Laboratories's top competitors include Femasys, OncoHealth and Teal Health.
MTM Laboratories has 10 investors. Key investors include Roche, HBM Healthcare Investments, Wellington Partners Venture Capital, Gilde Healthcare, and Heidelberg Innovationsfonds Management.
Yes. MTM Laboratories was acquired by Roche in July 2011.
